Persistent STAT3 activation has been found in activated B-cell like diffuse large B cell tumors (DLBCL). To investigate whether genetic mutations play a role in aberrant STAT3 signaling in DLBCL, we bi-directionally sequenced all 24 exons of the STAT3 gene in DLBCL tumors (n = 40). We identified 2 novel point mutations in 2 separate (2/40; 5%) patients at exon 7 and 24. Point mutation 2552G.A was a silent mutation in the stop codon. Another heterozygous mutation 857T.A encoded a methionine substitution by lysine at codon 206 (M206K) in the coiled-coil domain of STAT3. We performed site directed mutagenesis to mutate wild type (WT) STAT3a and STAT3b at codon 206 and constructed stable cell lines by lentiviral transfection of STAT3a WT , STAT3a
Introduction
Diffuse large B cell lymphoma (DLBCL) is the most common type of adult non-Hodgkin lymphoma. Aberrant gene expression and mutations are involved in the pathogenesis of DLBCL and may have prognostic and therapeutic relevance. JAK2/STAT3 was shown to be highly activated in DLBCL patient samples and DLBCL cell lines [1] , [2] , [3] . A high expression of STAT3 protein in DLBCL tumors as detected by immunohistochemistry (IHC) has been associated with unfavorable prognosis in DLBCL in some [4] , but not all studies [3] . More importantly, the presence of activated STAT3 in some cases and the availability of inhibitors of the pathway have paved the way for treatment trials [5] , [6] , [7] . Clarifying the mechanism for STAT3 activation may also assist in choosing patients who may benefit from these targeted therapies. We have demonstrated that elevated serum interleukin 10 (IL-10) is one cause for constitutive STAT3 activation [8] . However, not all DLBCL patients had a high serum IL-10. Mutations specifically missense mutations (which leads to amino acid changes) in JAK2 and STAT3 are another potential cause of STAT3 activation. Our lab has recently showed that there are no JAK2 activating missense mutations in DLBCL tumors [9] . STAT3 mutations have been reported in different kind of hematological malignancies. 30% patients with chronic lymphoproliferative disorders of natural killer cells had STAT3 activating missense mutations [10] . STAT3 mutations have also been described to activate STAT3 in a subset (40%) of patients with T-cell large granular lymphocytic leukemia [11] . The presence of STAT3 mutations in DLBCL tumors has recently described.
Morin et al, found that one out of 13 DLBCL tumors had STAT3 mutation [12] , similarly Lohr et al found 5 STAT3 mutations from 55 DLBCL cases [13] . However, there is still no data available on the functional relevance of these STAT3 mutations. In this study we detected STAT3 mutations by sequencing in 40 DLBCL patient tumors and determined the functional relevance of STAT3 mutations in DLBCL.
Materials and Methods

Patient samples
Cells from 40 DLBCL tumors were obtained from the Iowa/ Mayo Lymphoma SPORE Biobank. The Mayo Institutional Review Board (IRB) committee approved the use of human tissue samples for this study. Patients providing written informed consent were eligible for this study if they had a biopsy that upon pathologic review showed DLBCL.
Cell lines
The OCI-Ly3 (Ly3) and SUDHL2 (DHL2) DLBCL cell lines were a kind gift from Dr. Louis Staudt (NCI, Bethesda) [1] . Ly3 was cultured in Iscove's Modified Dulbecco's Media supplemented with 20% human serum. HEK-293T cell line was from Open Biosystem (Huntsville, AL, USA) and was grown in the Dulbecco's Modified Eagle Medium supplemented with 10% Fetal Bovine Serum.
Antibodies and reagents
Antibodies of pSTAT3 Y705 , STAT3, HDAC2, GAPDH were from Cell Signaling Technology (Beverly, MA, USA). Beta-Actin antibody was purchased from Santa Cruz (Santa Cruz, CA, USA). Recombinant human IL-10 was from R&D Systems (Minneapolis, MN, USA). TG101348 (TG) was a gift from TargeGEN Pharmaceuticals (now Sanofi-Aventis) (San Diego, CA, USA). TG has now been renamed SAR302503.
Analysis of STAT3 mutations in DLBCL tumors
We PCR-amplified all 24 exons of the STAT3 gene from the 40 DLBCL tumors. The PCR fragments were sequenced and analyzed at the Mayo Clinic Cancer Center Gene Analysis Core Facility. Site directed mutagenesis to create STAT3a and STAT3b mutants
The coding region of STAT3a (NM_139276.2) and STAT3b (NM_213662.1) were amplified and cloned into vector TOPO TA (Invitrogen, Grand Island, NY, US). The 617T.A mutation in the coding region of STAT3a and STAT3b was created with QuikChange II Site-Directed Mutagenesis Kits (Agilent, Santa Clara, CA, USA). WT and mutant genes were then cloned into lentiviral vector pLEX-MCS (Open Biosystem, Huntsville, AL, USA). 
Lentiviral stable transfection
Western Blotting
The cells were washed with ice-cold PBS before lysate with RIPA buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 15 mM Sodium molybdate) containing Protease Inhibitor Cocktail (Roche Applied Science, Indianapolis, IN, USA), Phenylmethanesulfonyl fluoride (Sigma, St Louis, MO, USA) and Halt Phosphatase Inhibitor Cocktail (Thermo Scientific, Waltham, MA, USA). Proteins were quantified and run on 4-20% Mini-protein gels (Bio-Rad, Hercules, CA, USA), and immunoblotted with antibodies indicated.
Dual luciferase assay
Plasmid pGL3-rPap1 was a kind gift from Dr. Tavernier (Ghent University, Ghent, Belgium), which was constructed by insertion of a STAT3 responsible promoter, the promoter of rPap1, into pGL3 basic vector [14] , [15] . PLEX empty vector, STAT3a WT , and STAT3a
M206K were transiently transfected together with pGL4-Renilla and pGL3-rPap1 into Ly3 cells. Luciferase activity was measured with dual luciferase assay kit (Promega, Madison, WI, USA). Firefly luciferase activity of pGL3-rPap1 was normalized by Renilla luciferase activity of pGL4-Renilla, which was used as a transfection efficiency control.
Nuclear and cytoplasmic analysis
Nuclear and cytoplasmic extracts were separated with NE-PER nuclear and cytoplasmic extraction kit (Thermo Scientific, Waltham, MA, USA) as manufacturer's instruction.
Proliferation assay
After transfection with pLEX empty vector, pLEX-STAT3a WT and pLEX-STAT3a M206K , Ly3 cells (0.1 million/200 ml/well) were seeded into 96-well plate in 4 replicates and proliferation was assessed by 3 H-thymidine incorporation assay as described before [16] .
Results
Identification of STAT3 mutations in DLBCL tumors
To identify STAT3 mutations in DLBCL, we sequenced all exons of the STAT3 gene from 40 DLBCL tumors. Two novel point mutations, 857T.A and 2552G.A, were identified in two separate tumors. The point mutation 857T.A was located in the exon 7 and predicted a missense substitution of methionine by lysine at codon 206 (M206K) ( Figure 1A ). Chromatograms showed a single peak of nucleotide thymidine (T) at position 857 in WT STAT3 while there were both nucleotide adenosine (A) and T peaks at position 857 in mutant STAT3. These results indicated that the mutation was heterozygous ( Figure 1B) . Modular structure indicates that this M206K STAT3 mutation is located near a nuclear localization signal (NLS) in the coiled-coil domain of STAT3 ( Figure 1C) . The coiled-coil domain of STAT3 is essential for STAT3 nuclear translocation and retention [17] , [18] , [19] , and is also involved in the recruitment of STAT3 to receptors when activated by cytokines [15] , [20] . Alignment analysis showed that Met206 (M206) is a conserved amino acid across STAT3 proteins from different species ( Figure 1C) .
Another STAT3 mutation 2552G.A was located in the stop codon and didn't predict a missense substitution. Chromatogram shows that the nucleotide at position 2552 is guanosine (G) in WT STAT3 and both G and A in mutant STAT3 (Figure 2) , suggesting that it is a heterozygous mutation. The 2552G.A mutation leads to the stop codon TGA change to TAA, which is also a stop codon (Figure 2 ). This suggests that 2552G.A mutation is a synonymous mutation.
Effect of STAT3
M206K mutation on STAT3 signaling were constructed and stably overexpressed in HEK-293T cells ( Figure 3A) . Sequencing results showed that the nucleotide was T at position 857 in WT STAT3, while the nucleotide was A at position 857 in mutant STAT3, suggesting that the nucleotide at position 857 was successfully mutated ( Figure S1 ). As phosphorylation at tyrosine 705 is essential for activating STAT3, we checked the effect of STAT3 M206K mutation on the STAT3 tyrosine phosphorylation (pSTAT3). Figure 3B and vector alone-transfected cells. However, the pSTAT3 level was similar in both WT STAT3b
WT and mutant STAT3b M206K transfected cells ( Figure 3B) transfected cells ( Figure 3C ). These data suggest that the STAT3 M206K mutation activates STAT3 signaling through STAT3a but not STAT3b. Cytokines can also activate STAT3 and IL-10 plays a role in STAT3 activation in DLBCL cells [8] . To learn whether the STAT3 M206K mutation affects the response of STAT3 to cytokine, we treated the stably transfected HEK-293T transfected cells with IL-10 and found that the pSTAT3 WT and STAT3b M206K transfected cell lines did not respond to IL-10 treatment ( Figure 3D ). These data suggest that the STAT3 M206K mutation enhances STAT3a signaling in the presence of IL-10.
M206K mutation on STAT3 transactivation Activated STAT3 needs to translocate to the nucleus in order to activate target gene transcription. To determine if the STAT3 M206K mutation can increase the nuclear translocation of activated STAT3, we measured pSTAT3 levels in the nucleus and cytosol and found the pSTAT3 level was higher in both compartments in the STAT3a M206K transfected cells compared to STAT3a
WT transfected cells ( Figure 4A ). Next, in order to determine if nuclear STAT3a M206K can increase the transactivation activity of STAT3a, a STAT3-driven luciferase reporter construct along with pLEX-STAT3a
WT or pLEX-STAT3a
M206K
was transfected into Ly3 cells. We found that STAT3 transactivation activity was higher in mutant STAT3a M206K transfected cells in response to IL-10 as compared to that in WT STAT3a WT transfected cells ( Figure 4B ). Constitutively activated STAT3 can promote cell proliferation in DLBCL [2] . By use of H 3 -thymidine incorporation assay we determined that mutant STAT3a M206K further increased the proliferation of Ly3 cells compared to WT STAT3a WT ( Figure 4C ). These data indicate that the STAT3 M206K mutation has functional consequences by activating the transactivation activity of STAT3a and increasing cell proliferation.
Effect of STAT3a
M206K mutation on JAK2 inhibition
To test whether the deregulated STAT3 signaling by STAT3 M206K mutation can be blocked by an inhibitor of the JAK2 signaling pathway, we treated STAT3a
WT and STAT3a
M206K
stably transfected HEK-283T cells with TG101348, an inhibitor of JAK2 [21] , [22] , [23] . As expected, WT STAT3a WT cells were WT and STAT3a M206K along with a STAT3 luciferase reporter followed by IL-10 treatment for 6 hours and cells were used for luciferase assay. Bars represent mean 6 SD from 3 replicates. Data was repeated three times (**P = 0.0042; ***P,0.001). The data were analyzed by the two-tailed unpaired Student's t test. (C) The effect of WT STAT3a
WT and mutant STAT3a M206K on Ly3 cells proliferation by H 3 -thymidine incorporation assay. Bars represent mean 6 SD from 4 replicates. The experiment was repeated three times (*P = 0.013). The data were analyzed by the two-tailed unpaired Student's t test. doi:10.1371/journal.pone.0067851.g004 very sensitive to JAK2 inhibition and pSTAT3a was completely inhibited with TG101348 treatment. However STAT3a M206K mutant cells were resistant to JAK2 inhibition and TG101348 treatment was not able to completely dephosphorylate STAT3 ( Figure 5A ). More or less similar results were found when we transiently transfected WT STAT3a
WT and mutant STAT3a M206K into the Ly3 cells and treated with JAK2 inhibitor ( Figure 5B ). These data suggest that mutant STAT3a M206K are resistant to JAK2 inhibition.
We then checked whether overexpression of the STAT3a M206K mutant could rescue the JAK2 inhibition mediated cell growth. Proliferation of mutant STAT3a M206K transfected Ly3 were less inhibited compared to that of vector only or WT STAT3a WT transfected cells specifically at 1 mM TG101348 concentration ( Figure 5C ). When treated with 1 mM TG101348, approximately 50% of the cell proliferation was inhibited in WT STAT3a WT transfected cells, while only 20% of the cell proliferation was inhibited when mutant STAT3a M206K was transfected into the cells ( Figure 5C ). These data suggest that mutant STAT3a
can partially rescue the JAK2 inhibition mediated cell growth.
Discussion
There are several potential mechanisms for aberrant JAK2/ STAT3 activation in DLBCL tumors including cytokines such as IL-10 [8], loss of negative regulators such as tyrosine phosphatases, and genetic mutations. We have previously demonstrated that JAK2 mutations are not the cause [9] ; however, there have been few reports on the role of STAT3 mutations in lymphoma in general and specifically DLBCL. Overall, we found two point mutations in STAT3 gene in 40 DLBCL tumors (5%) indicating that mutations in STAT3 in DLBCL tumors are uncommon. Out of these 2 STAT3 mutations only one mutation (M206K) was identified as a missesne mutation that was located in coiled-coil domain of STAT3 protein. Pasqualucci et al, found no somatic STAT3 mutations in their studies using next-generation sequencing on tumor cells from six DLBCL patients [24] . Morin et al found one of 13 cases studied to have a missense mutation that resulted in mutation of serine to arginine at codon 614 [12] . Lohr et al. sequenced 55 DLBCL cases and found 5 that had STAT3 mutations [13] . Four of these were missense mutations (R152W, K658R, H447Y, R278H) and the other case had a deletion, E616del. A previous study reported a STAT3 missense mutation (R382Q) in a DLBCL patient with hyper-immunoglobulin E syndrome (Hyper IgE) [25] . Interestingly, 2 out of the 7 missense mutations (28%) reported so far in DLBCL were located in the coiled-coil domain. Although there have been 6 reported cases of missense STAT3 mutations in patients with DLBCL, there have been no reports of the functional relevance of these mutations. We have demonstrated that the M206K STAT3 mutation in DLBCL was able to activate STAT3 signaling resulting in an increase cell proliferation. The mutation also made the cells more resistant to JAK2 inhibition with the novel catalytic site JAK2 inhibitor TG101348 now in clinical trial for myeloproliferative neoplasms. STAT3 mutations are thus another potential mechanism of STAT3 activation in DLBCL. Although we have shown the functional relevance of the M206K STAT3 mutation, the functional consequences of other STAT3 mutations have not been described to date. 
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